SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trimeris (TRMS)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Doms who wrote (95)9/13/2000 8:27:28 AM
From: Pluvia  Read Replies (1) of 108
 
Mark,

Thank goodness Pluvia (someone in Las Vegas) has caught a fundamental error that has fooled Roche, NIH, and, well, just about anybody else in the HIV scientific community (I am not a member of that community, but a close relative is). Pretty amazing, isn't it?

Now that's not nice. Remember with a 1.2 million population there are a few smart guys in Vegas... I recall Howard Hughes lived there...

As too your argument that since Roche continues with TRMS it means the trials were not flawed... Come on now, that's a little thin don't you think?

1. I spoke to 4 of the PI's who ran the flawed T-20 trials.

2. They all agreed the trial was flawed because it used two variables, and that the use of new anti-HIV cocktail, (as demonstrated by Durant's study), should have been given credit for part of the anti-HIV results shown in the trials.

Mark, I guess my point is... If the MD's who ran the trials agree the trial design was flawed and results cannot be attributed to T-20, why attack me for pointing this out?

Heck go after them, they all list their phone numbers on the Trimeris website.

Good Luck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext